Caldwell Sutter Capital’s Spruce Biosciences SPRB Stock Holding History

Caldwell Sutter Capital’s Portfolio SPRB Stock Details SPRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$632	Hold	13	–	–	﹤0.01%	905
2026 Q2	$702	Hold	13	–	–	﹤0.01%	877
2026 Q1	$850	Hold	13	–	–	﹤0.01%	826
2025 Q4	$1.13K	Hold	13	–	–	﹤0.01%	796
2025 Q3	$116	Hold	13	–	–	﹤0.01%	849
2025 Q2	$73	Hold	13	–	–	﹤0.01%	836
2025 Q1	$290	Hold	13	–	–	﹤0.01%	848
2024 Q4	$420	Hold	13	–	–	﹤0.01%	854
2024 Q3	$475	Hold	13	–	–	﹤0.01%	857
2024 Q2	$518	Hold	13	–	–	﹤0.01%	864
2024 Q1	$786	Hold	13	–	–	﹤0.01%	837
2023 Q4	$2.93K	Hold	13	–	–	﹤0.01%	704
2023 Q3	$2.26K	Hold	13	–	–	﹤0.01%	714
2023 Q2	$2.15K	Buy	+13	New	+$2.17K	﹤0.01%	735

Other funds holding SPRB

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return

Quinn Opportunity Partners Charlottesville, Virginia $1.85B AUM 1.27% 1-Year Est. Return

DMKJ

David M. Knott Jr $183M AUM 73.23% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Persistent Asset Partners Hong Kong $362M AUM 191.92% 1-Year Est. Return

Caldwell Sutter Capital's SPRB Position: Q3 2026 in Review

Caldwell Sutter Capital held its Spruce Biosciences (SPRB) position steady in Q3 2026 at 13 shares worth $632. The position accounts for ﹤0.01% of the portfolio, ranked #905.

Caldwell Sutter Capital first reported a position in SPRB in Q2 2023 and has held it in 14 quarters since. The position peaked at $2.93K in Q4 2023. 40 funds tracked by Wall St. Rank hold SPRB as of Q3 2026.

Caldwell Sutter Capital held 13 shares of Spruce Biosciences worth $632 as of Q3 2026.
Caldwell Sutter Capital left its Spruce Biosciences share count unchanged in Q3 2026.
Spruce Biosciences made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q3 2026, its #905 holding.
Caldwell Sutter Capital first reported a position in Spruce Biosciences in Q2 2023 and has held it in 14 quarters since.
Caldwell Sutter Capital's Spruce Biosciences position peaked at $2.93K in Q4 2023.
40 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2026.

Based on Caldwell Sutter Capital's 13F filing for Q3 2026, filed 9 Nov 2026.